Showing results (281-290 of 317) with videos related to

Sort By:
Pageof 32
JCO Precision Oncology|June 27, 2024
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH TrialKieuhoa T Vo, Amit J Sabnis, P Mickey Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2022
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH TrialD Williams Parsons, Katherine A Janeway, David R Patton, et al.
Blood|January 9, 2010
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AMLJessica A Pollard, Todd A Alonzo, Robert B Gerbing, et al.
JCO Precision Oncology|September 19, 2024
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621DTheodore W Laetsch, Kathleen Ludwig, P Mickey Williams, et al.
The Oncologist|May 30, 2024
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trialJulia L Glade Bender, Kerice Pinkney, Paul M Williams, et al.
Cancer|October 30, 2019
Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task ForceEtan Orgel, Thomas B Alexander, Brent L Wood, et al.
Science Advances|January 10, 2024
Universal pictures: A lithophane codex helps teenagers with blindness visualize nanoscopic systemsEmily A Alonzo, Travis J Lato, Mayte Gonzalez, et al.
Blood Advances|May 5, 2026
Combining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemiaNastassja Keora Scheidegger, Constanze Schneider, Gabriela Alexe, et al.
Journal of the National Cancer Institute|May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621CSusan N Chi, Joanna S Yi, P Mickey Williams, et al.
The Oncologist|June 14, 2024
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm GMarie V Nelson, AeRang Kim, P Mickey Williams, et al.
Pageof 32